Adarza to commercialize diagnostic assays in 2019

Adarza, a Serra Capital II portfolio company, is set to start selling its diagnostic assays next year. Adarza BioSystems, Inc. is a label-free platform technology that enables the simultaneous detection of hundreds of analytes in a single drop of fluid.

Adarza said its first products will be assays for detecting inflammation, cardiovascular disease and cancer. It expects the first customers to be university researchers and drug-development companies.


Adarza Biosystems Closes On $17 Million Series C Financing

Adarza, a Serra Capital II portfolio company, has closed $17M in Series C Financing. The company which is leading next generation innovator in label-free, multiplex assays, announced the financing on January 17.

Proceeds from the financing will be used to further expand production capacity in its St. Peters, Mo. manufacturing facility and fund final development and commercialization of Adarza’s first immunoassay product consumable and instrument platform. 


Serra Ventures Featured in St. Louis Business Journal

Serra Ventures had an exciting week of press for Serra Capital III, first with a feature in the Chicago Tribune on May 13, and then again in the St. Louis Business Journal on May 16. 

The May 16 article highlighted the fund's target size and amount of investments, and also included short descriptions of the Serra Capital I and II's St. Louis based companies Label Insight, Adarza Biosystems, Techli, and Tunespeak. 

Serra III intends to continue investing in the Midwest region. Tim Hoerr, Managing Partner of Serra, told the Chicago Tribune “The Midwest is the ripest ground for new tech innovation right now because it’s an emerging market. A lot of the capital in Chicago doesn’t stay here, and it should.”